Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib
- PMID: 32726663
- DOI: 10.1016/j.lfs.2020.118150
Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib
Retraction in
-
Retraction notice to "Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib" [Life Sci. 259 (2020) 118150].Life Sci. 2024 Aug 1;350:122773. doi: 10.1016/j.lfs.2024.122773. Epub 2024 Jun 6. Life Sci. 2024. PMID: 38845263 No abstract available.
Abstract
Conventional therapeutic methods against cancer, including chemotherapy, radiotherapy, surgery, and combination therapy, have exhibited different toxicity levels due to their unspecific mechanism of action. To overcome the challenges facing conventional cancer therapies, newly developed methods are being investigated. Significant levels of specificity, remarkable accumulation at the tumor site, limited side effects, and minimal off-target effects enable the newly synthesized nanoparticles (NPs) to become the preferred drug delivery method in anticancer therapeutic approaches. According to the literature, CD73 has a pivotal role in cancer progression and resistance to chemotherapy and radiotherapy. Therefore, CD73 has attracted considerable attention among scientists to target this molecule. Accordingly, FDA approved CDK inhibitors such as Dinaciclib that blocks CDK1, 2, 5, and 9, and exhibits significant anticancer activity. So in this study, we intended to simultaneously suppress CD73 and CDKs in cancer cells by using the folic acid (FA)-conjugated chitosan-lactate (CL) NPs loaded with anti-CD73 siRNA and Dinaciclib to control tumor progression and metastasis. The results showed that NPs could effectively transfect cancer cells in a FA receptor-dependent manner leading to suppression of proliferation, survival, migration, and metastatic potential. Moreover, the treatment of tumor-bearing mice with this combination strategy robustly inhibited tumor growth and enhanced survival time in mice. These findings imply the high potential of FA-CL NPs loaded with anti-CD73 siRNA and Dinaciclib for use in cancer treatment shortly.
Keywords: Adenosine; CD73; CDK; Cancer; Dinaciclib; Nanoparticle.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare no conflict of interest.
Similar articles
-
Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.Int J Biol Macromol. 2021 Sep 1;186:849-863. doi: 10.1016/j.ijbiomac.2021.07.034. Epub 2021 Jul 7. Int J Biol Macromol. 2021. PMID: 34245737
-
Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.Pharm Res. 2020 Sep 17;37(10):196. doi: 10.1007/s11095-020-02892-y. Pharm Res. 2020. Retraction in: Pharm Res. 2022 Dec;39(12):3383-3384. doi: 10.1007/s11095-022-03432-6. PMID: 32944844 Retracted.
-
Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies.Drug Discov Today. 2017 Nov;22(11):1686-1696. doi: 10.1016/j.drudis.2017.06.005. Epub 2017 Jul 1. Drug Discov Today. 2017. PMID: 28676406 Review.
-
Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.Oncotarget. 2016 Aug 30;7(35):56864-56875. doi: 10.18632/oncotarget.10870. Oncotarget. 2016. PMID: 27486754 Free PMC article.
-
Dinaciclib for the treatment of breast cancer.Expert Opin Investig Drugs. 2014 Sep;23(9):1305-12. doi: 10.1517/13543784.2014.948152. Epub 2014 Aug 8. Expert Opin Investig Drugs. 2014. PMID: 25107301 Review.
Cited by
-
A comprehensive review on RNA interference-mediated targeting of interleukins and its potential therapeutic implications in colon cancer.3 Biotech. 2023 Jan;13(1):18. doi: 10.1007/s13205-022-03421-x. Epub 2022 Dec 20. 3 Biotech. 2023. PMID: 36568500 Free PMC article. Review.
-
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.J Nanobiotechnology. 2022 Sep 24;20(1):423. doi: 10.1186/s12951-022-01626-z. J Nanobiotechnology. 2022. PMID: 36153528 Free PMC article. Review.
-
Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.Pharm Res. 2022 Aug;39(8):1851-1866. doi: 10.1007/s11095-022-03297-9. Epub 2022 Jun 17. Pharm Res. 2022. Retraction in: Pharm Res. 2024 Feb;41(2):407-408. doi: 10.1007/s11095-023-03647-1. PMID: 35715669 Retracted.
-
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery.Pharmaceutics. 2021 Mar 3;13(3):326. doi: 10.3390/pharmaceutics13030326. Pharmaceutics. 2021. PMID: 33802531 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous